Key Takeaways:
Innovent Biologics (1801.HK) secured its tenth approval for the cancer drug TYVYT in China for a new combination therapy to treat advanced renal cell carcinoma.
"The approval...broadens treatment options for Chinese patients with advanced kidney cancer," the company said in a statement, referencing the positive results from the FRUSICA-2 clinical trial.
The approval combines TYVYT (sintilimab) with ELUNATE (fruquintinib) for patients with locally advanced or metastatic renal cell carcinoma who have failed prior VEGFR-TKI therapy. The underlying Phase III FRUSICA-2 study showed the combination more than tripled median progression-free survival compared to standard treatments like axitinib or everolimus, while also delivering higher response rates.
The approval strengthens Innovent’s position in China's large immuno-oncology market and further validates its combination-therapy strategy. Shares of Innovent rose as much as 3.97% in Hong Kong trading following the news.
The new indication for the sintilimab–fruquintinib regimen, now cleared for two hard-to-treat cancers, reinforces Innovent’s strategy of developing combination regimens. The company, which collaborates with multinational partners like Eli Lilly, is a major player in China's biopharmaceutical sector, focusing on developing and commercializing innovative oncology therapies.
The expanded label for TYVYT is expected to accelerate its revenue growth and solidify its market share against domestic and international competitors. Investors will now watch for the commercial uptake and sales data from this new indication in the company's upcoming quarterly reports.
This article is for informational purposes only and does not constitute investment advice.
